The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Early systemic treatment and IO hold promise for improving outcomes for biliary tract cancer
Thorsten Goetze, MD, The University Cancer Center Frankfurt, Frankfurt, Germany, highlights that the most pressing unmet need in biliary tract cancer management is the high mortality rate among patients, which necessitates early systemic treatment. He suggests that neoadjuvant treatment combined with immunotherapy may hold promise for improving prognosis, and emphasizes the need for larger trials to validate this approach. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The most important thing in gallbladder tract cancer is the point that most of the patients will die early in the case. And therefore it’s an early systemic disease and caused by this fact, I think we have to treat the patients where we are on the coast with a systemic therapy and maybe then combined due to both the two studies with a neoadjuvant treatment and in addition neoadjuvant treatment combined with a neoadjuvant immunotherapy...
The most important thing in gallbladder tract cancer is the point that most of the patients will die early in the case. And therefore it’s an early systemic disease and caused by this fact, I think we have to treat the patients where we are on the coast with a systemic therapy and maybe then combined due to both the two studies with a neoadjuvant treatment and in addition neoadjuvant treatment combined with a neoadjuvant immunotherapy. And therefore, this is, I think, the future. Neoadjuvant treatment combines with immunotherapy. So we need a bigger trial, combining those two regimens and to improve the prognosis of this disease.
Read more...
